Oncorus is developing potent oncolytic viro-immunotherapies for the treatment of cancers with significant unmet medical need
Oncolytic viruses (OVs) represent a new class of therapeutic agents in the arsenal of drugs against cancer. Oncorus has developed a robust OV platform, including a novel approach to maintain safety while enhancing oncolytic potency by leveraging the differential expression of micro-RNA (miR) sequences.
Oncorus' armed OVs infect and conditionally replicate in tumor cells, resulting in tumor cell lysis. Upon lysis, multiple tumor antigens and therapeutic immune modulatory payloads are released into the local environment. Tumor antigens and immune payloads stimulate and recruit immune cells to destroy tumor and distant metastasis, resulting in a highly effective cancer therapy.
Harnessing the full potential of OVs developing best-in-class next-gen OVs. Oncorus' platform incorporates multiple innovative modifications to enhance efficacy while maintaining safety.
ONCORUS INNOVATION: miR ATTENUATION
Oncorus' innovative miR-attenuation strategy enables robust viral replication in tumor cells, while preventing replication in healthy normal tissue.
miR-sequences are small non-coding RNA sequences involved in mRNA silencing, acting as “master regulators” of cell fate. In tumors, expression of specific miRs are lost. Oncorus has incorporated multiple miR-target (miR-T) sequences within one of more essential viral genes of our viruses, thus inhibiting viral replication in key normal tissues, while enabling selective and potent oncolysis of tumor cells.
Oncorus’ oncolytic herpes simplex viruses (oHSVs) were grown in the presence or absence of CNS and liver specific miR sequences. For in vitro experimentation, miR expression was modulated with transfected miR mimics.